新冠病毒疫苗类型对吉兰-巴雷综合征的影响：两例病例及文献复习。
Effects of COVID-19 vaccine type on Guillain-Barré syndrome: Two cases and a literature review.
机构信息
Department of Emergency Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Department of Emergency Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
出版信息
Hum Vaccin Immunother. 2023 Dec 31;19(1):2171231. doi: 10.1080/21645515.2023.2171231. Epub 2023 Feb 22.
Guillain-Barré syndrome (GBS) is a rare but severe complication of COVID-19 vaccination. We report two cases of GBS following vaccination with the adenovirus vector vaccine ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca) and review the relevant literature. Relevant studies published between December 2020 and May 2022 including 881 patients with GBS were reviewed. GBS incidence and the need for mechanical ventilation were reported at a higher level among patients receiving Vaxzevria (n = 400). However, incidence cannot be accurately estimated from case reports. Thus, the true GBS rates following COVID-19 vaccination should be determined by population-based data.
格林-巴利综合征（GBS）是 COVID-19 疫苗接种的罕见但严重的并发症。我们报告了两例腺病毒载体疫苗 ChAdOx1 nCoV-19（Vaxzevria，阿斯利康）接种后发生的 GBS，并复习了相关文献。复习了 2020 年 12 月至 2022 年 5 月期间发表的包括 881 例 GBS 患者的相关研究。报告称，接受 Vaxzevria（n=400）治疗的患者中，GBS 的发生率和需要机械通气的比例更高。然而，从病例报告中无法准确估计发病率。因此，应通过基于人群的数据来确定 COVID-19 疫苗接种后的真实 GBS 发生率。
Zotero 插件